Research programme: infectious disease vaccine - Codagenix

Drug Profile

Research programme: infectious disease vaccine - Codagenix

Alternative Names: CDX EC; CDX H7N9; CDX-DENV-14; CDX-RSV-A; CDX-ZiKV; CDX-ZKV

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Codagenix
  • Class Dengue vaccines; Escherichia coli vaccines; Influenza A virus H7N9 vaccines; Respiratory syncytial virus vaccines; Vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue; Escherichia coli infections; Respiratory syncytial virus infections; Zika virus infection
  • Research Influenza A virus H7N9 subtype

Most Recent Events

  • 27 Feb 2018 Early research in Influenza-A virus H7N9 subtype (Prevention) in USA before February 2018 (Codagenix pipeline, February 2018)
  • 23 Jan 2018 Codagenix plans a phase I/II trial for Respiratory syncytial virus infections in the fourth quarter of 2018
  • 23 Jan 2018 Codagenix plans a phase I/II trial for Zika virus infection in the first quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top